Health
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model
Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEW
About this update from Ibio, Inc.
[{"type":"image","alt":"iBio, Inc.","displaySize":"","headline":null,"caption":"iBio, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":170,"url":"https://media.zenfs.com/en/globenewswire.com/7b73f55b88269d5e23378e624b0ffcac"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SJdaoYV8WWMD9fxupwqycw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7b73f55b88269d5e23378e624b0ffcac","width":300,"height":170}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscle","length":256,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone","length":209,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":465,"olType":false},{"type":"text","content":"SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced new promising preclinical data for its first-in-class Activin E antibody unveiled in January. Data from the recently completed 4-week study in diet-induced obese mice show a 26% reduction in fat mass following treatment with the Activin E antibody, with muscle mass fully preserved. These findings highlight a significant fat loss can be achieved without the double-digit weight reductions typically required by other obesity drugs.","length":580,"tagName":"p"},{"type":"text","content":"GLP-1 receptor agonists are effective at promoting weight loss. However, they can also reduce lean body mass, including muscle, which may limit some of the intended health benefits. In contrast, fat-specific weight loss is considered a higher-quality form of weight loss. It reduces fat—linked to lower risk of heart and metabolic diseases—while preserving muscle, which helps maintain strength, supports a healthy metabolism, and may prevent or reduce weight regain over time.","length":477,"tagName":"p"},{"type":"text","content":"“We...